126.89
2.12%
+2.4519
Transmedics Group Inc stock is currently priced at $126.89, with a 24-hour trading volume of 961.10K.
It has seen a +2.12% increased in the last 24 hours and a +68.66% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $121.7 pivot point. If it approaches the $127.3 resistance level, significant changes may occur.
Previous Close:
$124.44
Open:
$125
24h Volume:
961.10K
Market Cap:
$4.25B
Revenue:
$296.92M
Net Income/Loss:
$-10.20M
P/E Ratio:
-115.36
EPS:
-1.1
Net Cash Flow:
$-192.09M
1W Performance:
+38.01%
1M Performance:
+68.66%
6M Performance:
+198.18%
1Y Performance:
+74.04%
Transmedics Group Inc Stock (TMDX) Company Profile
Name
Transmedics Group Inc
Sector
Industry
Phone
978-552-0900
Address
200 Minuteman Road, Suite 302, Andover, MA
Transmedics Group Inc Stock (TMDX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jul-19-23 | Initiated | Robert W. Baird | Outperform |
Aug-02-22 | Upgrade | JP Morgan | Neutral → Overweight |
Oct-08-20 | Downgrade | JP Morgan | Overweight → Neutral |
Apr-07-20 | Initiated | Oppenheimer | Outperform |
May-28-19 | Initiated | Canaccord Genuity | Buy |
May-28-19 | Initiated | Cowen | Outperform |
May-28-19 | Initiated | JP Morgan | Overweight |
May-28-19 | Initiated | Morgan Stanley | Equal-Weight |
View All
Transmedics Group Inc Stock (TMDX) Latest News
Will TransMedics (TMDX) Gain on Rising Earnings Estimates?
Zacks Investment Research
Illumina (ILMN) Q1 Earnings Beat, Adjusted Operating Loss Widens
Zacks Investment Research
Tandem Diabetes (TNDM) Posts Narrower Q1 Loss, Raises '24 View
Zacks Investment Research
TransMedics Group, Inc. (TMDX) Soars to 52-Week High, Time to Cash Out?
Zacks Investment Research
Is TransMedics (TMDX) a Buy as Wall Street Analysts Look Optimistic?
Zacks Investment Research
Why TransMedics Stock Is Soaring Today
The Motley Fool
Transmedics Group Inc Stock (TMDX) Financials Data
Transmedics Group Inc (TMDX) Revenue 2024
TMDX reported a revenue (TTM) of $296.92 million for the quarter ending March 31, 2024, a +149.23% rise year-over-year.
Transmedics Group Inc (TMDX) Net Income 2024
TMDX net income (TTM) was -$10.20 million for the quarter ending March 31, 2024, a +63.98% increase year-over-year.
Transmedics Group Inc (TMDX) Cash Flow 2024
TMDX recorded a free cash flow (TTM) of -$192.09 million for the quarter ending December 31, 2023, a -232.77% decrease year-over-year.
Transmedics Group Inc (TMDX) Earnings per Share 2024
TMDX earnings per share (TTM) was -$0.34 for the quarter ending March 31, 2024, a +64.21% growth year-over-year.
About Transmedics Group Inc
Transmedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers. The company offers its products in the United States and internationally. Transmedics Group, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.
Cap:
|
Volume (24h):